Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 1999

View Archived Issues

Quetiapine as a treatment for drug-induced psychosis in PD

Trimeris initiates patient selection and dosing in T-20 phase II trial

FDA approves 15-mg Ditropan XL tablets

QLT terminates collaboration with Beaufour Ipsen

ICAgen licenses novel ion channel genes from SUNY

New hepatitis A vaccine affords protection with first dose

Shire reports positive phase II results for Lambda

FeRx's targeted carrier tested in doxorubicin delivery to liver cancer patients

Ziagen approved in Canada in combination therapy for HIV/AIDS therapy

BMS withdraws from brasofensine collaboration with NeuroSearch

Lundbeck develops radiolabeled 5-HT2 receptor antagonist for PET studies

Enzon and Schering-Plough revise agreement for PEG-Intron

InKine's CBP-1011 to continue phase III development

Genentech submits NDA to FDA for Nutropin Depot

Multifunctional antiinflammatory agents in development at ADIR

New benzothiophene ET antagonists from Pfizer

Shiseido describes new gastric antisecretory agents for ulcers

Orphanin FQ receptor ligands designed at Roche for therapeutic use

Lilly patents new series of selective beta3-agonists for diabetes, obesity

New compounds from Merck inhibit posttranslational farnesylation of proteins

Piperidines synthesized at Toa Eiyo act as 5-HT2 antagonists and antiplatelet agents

Australian team presents in vivo results with new, orally active C5a receptor antagonist

Dusa receives FDA approvable letter for Levulan NDA

Aronex reports responses in phase II trial of Atragen as treatment of NHL

Merckle cPLA2 inhibitor demonstrates both acute antiinflammatory and antiasthmatic effects

SmithKline Beecham launches new combined vaccine for hepatitis A and typhoid in the U.K.

R-146225: orally active inhibitor of both IL-5 protein and mRNA production

Xoma licenses use of recombinant BPI to Allergan for ophthalmic infections

Nitroderivative of aspirin endowed with significant myocardial protective effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...